Clinical Trials

35 enrolled

Phase 2 Active not recruiting

Rectal Neoplasms

NCT05507632 2026-06-01

Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular Carcinoma

48 enrolled

Carcinoma, Hepatocellular

NCT07594925 2026-05-19

Short-Course Radiotherapy Followed by Immunotherapy Combined With Chemotherapy for Microsatellite Stable Locally Advanced Rectal Cancer: A Prospective, Randomized, Controlled Phase II Clinical Trial

130 enrolled

Rectal Neoplasms

NCT07584018 2026-05-13

The DoHAICs Study Expansion Phase

90 enrolled

Carcinoma, Hepatocellular

NCT06050317 2026-05-01

Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer

25 enrolled

Pancreatic Neoplasms

NCT07560488 2026-05-01

Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma

43 enrolled

Carcinoma, Hepatocellular

NCT05357846 2026-04-30

PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)

Phase 3 Recruiting

422 enrolled

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT06356584 2026-04-28

Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases

62 enrolled

Colorectal Neoplasms

NCT06204094 2026-04-24

CASINOs

37 enrolled

Rectal Neoplasms

NCT07521852 2026-04-22

A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC

40 enrolled

Carcinoma, Hepatocellular, Neoplasms

NCT06860490 2026-04-21

HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)

164 enrolled

Carcinoma, Hepatocellular

NCT07535632 2026-04-17

BEST

58 enrolled

Phase 3 Not yet recruiting

Colorectal Neoplasms

NCT07537946 2026-04-17

Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer

400 enrolled

Carcinoma, Hepatocellular, Neoplasm Metastasis

NCT07537972 2026-04-17

Denosumab Strategy for Liver Cancer With Bone Metastases

50 enrolled

Carcinoma, Hepatocellular

NCT07490262 2026-04-16

A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.

Phase 2/3 Recruiting

680 enrolled

Phase 1/2 Not yet recruiting

Carcinoma, Hepatocellular

NCT07522411 2026-04-13

Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma

100 enrolled

Carcinoma, Hepatocellular

NCT07506109 2026-04-07

A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer

49 enrolled

Spinocerebellar Degenerations, Colorectal Neoplasms

NCT07515625 2026-04-07

Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma

46 enrolled

Stomach Neoplasms

NCT07509424 2026-04-03

Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance

29 enrolled

Rectal Neoplasms

NCT07331883 2026-03-27

Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)

35 enrolled

GastrointestinalGynecologic

Carcinoma, Hepatocellular

NCT05427487 2026-03-25

Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours

Phase 1 Recruiting

70 enrolled

Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT07492615 2026-03-25

A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma

276 enrolled

Stomach Neoplasms

NCT07490990 2026-03-24

A Real-World, Single-Arm Study Protocol of Disitamab Vedotin in Combination With Immunotherapy and Multimodal Radiation Therapy for HER2-Positive Advanced Gastric Cancer: After Second-Line Treatment Failure

Not yet recruiting

30 enrolled

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

NCT04720716 2026-03-19

A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC

Phase 3 Completed

344 enrolled

Carcinoma, Hepatocellular

NCT06497985 2026-03-19

A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients

Phase 3 Recruiting

430 enrolled

Colorectal Neoplasms

NCT07474103 2026-03-16

SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC

Phase NA Recruiting

49 enrolled